Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Arena Pharma cuts to the bone
by Lisa M. Jarvis
July 11, 2016
| A version of this story appeared in
Volume 94, Issue 28
Narrowing its focus to its clinical-stage pipeline, Arena Pharmaceuticals will lay off 100 people, or 73% of its workforce. The cuts are expected to save Arena $17 million annually. The reductions come on top of the 80 researchers the San Diego biotech firm laid off in November as it tries to support the development of three compounds in early and midstage clinical trials. Arena and its partner Eisai received FDA approval in 2012 for the weight loss pill Belviq, but the drug has not been a commercial success.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter